VermaS,PoulterNR,BhattDL,BainSC,BuseJB,LeiterLA,etal.Effects of liraglutide on cardiovascular outcomes in patients with type 2 diabetes mellitus with or without history of myocardial infarction or stroke: Post hoc analy- sis from the leader trial.Circulation.2018;138:288494, .MannJFE,FonsecaV,MosenzonO,RazI,GoldmanB,IdornT,etal.Effects of liraglutide versus placebo on cardiovascular events in patients with type 2 dia- betes mellitus and chronic kidney disease: Results from the LEADER trial.Circulation.2018;138:290818, VermaS,BhattDL,BainSC,BuseJB,MannJFE,MarsoSP,etal.Effect of liraglutide on cardiovascular events in patients with type 2 diabetes mellitus and polyvascular disease.Circulation.2018;137:217983, Funding This work was supported by the Instituto de Salud Carlos III (PI19/01375) co-financed with FEDER programme fund
Since beginning his legal career in 1997, Mr
This proved it to have fewer severe side effects in clinical trials and to cause less weight gain than other existing diabetics drugs
Transparent pricing on generics and especially low-cost insulin, for patients who already have a prescription
